Drug Profile


Alternative Names: AEGR 427 implitapide; AEGR-427; BAY 13-9952

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antihyperlipidaemics; Indoles; Pyridines
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type II
  • New Molecular Entity No

Highest Development Phases

  • Suspended Hypercholesterolaemia
  • Discontinued Hyperlipidaemia; Hyperlipoproteinaemia type II; Hypertriglyceridaemia

Most Recent Events

  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 31 Dec 2011 Suspended - Phase-II for Hypercholesterolaemia in USA (PO)
  • 07 Feb 2007 Phase-II clinical trials in Hypercholesterolaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top